The effects of prostaglandin E1 (PGE1) and indomethacin (IDM) on the release of several pituitary hormones from the rat pituitary were investigated in vitro.
hormone
(GH) and prolactin, but not of adrenocorticotropin (ACTH) and luteinizing hormone (LH) . Although the addition of 1ƒÊg/ml of IDM alone resulted in no effect on the basal release of these hormones, IDM diminished the release of ACTH induced by crude rat hypothalamic extracts (HE) or lysine-8-vasopressin (LVP), and LH induced by HE or luteinizing hormone-releasing hormone (LH-RH).
These findings implicate that a part of PGE1 action might be a direct one on the pituitary gland and PGE1 might release GH and prolactin, whereas IDM might have a direct action on the pituitary gland, and that blunt the release of these pituitary hormones induced by several stimuli.
It is well known that prostaglandins(PGs) exist in most parts of living tissues (Shaws et al., 1971; Butcher and Baired, 1968) and have hormone-like action which may be mediated by activation of adenylcyclasecyclic AMP system in various endocrine glands (Zor et al., 1970; Marsh, 1971; Kaneko et al., 1969; Flack et al., 1969; McLeod and Lehmeyer, 1970) .
It is also reported that PGs are present in the hypothalamus and are released into the ventricle of the brain by several stimuli (Harms et al., 1973) , and that those of the E series may be potent inhibitors of sympathetic neuro-effector transmission (Hedqvist, 1973) . Thus, it is conceivable that PGs might be involved in regulating the release of pituitary hormones.
Indomethacin (IDM) is known to inhibit the synthesis of PGs (Vane, 1971) , and to affect on endocrine function is several glands. The purpose of the present study is to ascertain the action of prostaglandin E1 (PGE1) and IDM on the release of pituitary hormones from rat pituitary in vitro.
Materials and Methods
Male Sprague-Dawley rats (180-200g) were used as pituitary donors.
The pituitaries were obtained by decapitation and after removal of the posterior pituitary they were cut in half and a hemipituitary was placed in each beaker with 2ml of Krebs-Ringer bicarbonate medium containing 200mg/dl glucose and 0.25% bovine serum albumin (KRBG-BSA). Four beakers were used for each sample. After 45-min preincubations two times the medium was replaced by 1ml of KRBG-BSA and incubated for 30minutes.
The medium was decanted. Then 1ml KRBG-ESA or KRBG-BSA containing the test material was added to the beaker and incubated for 30minutes.
The amounts of ACTH, prolactin, GHand LH released into the medium during the second 30-min incubation were compared with those released during the first 30-min incubation and expressed as a percentage.
ACTH concentration in the medium was determined by radioimmunoassay as described by Ratcliffe (1971) . Prolactin, LH and GH were determined by radioimmunoassay using NIAMDD rat prolactin, LH and GH kits, respectively.
PGEi was obtained from Ono Pharmaceutical Ltd. and IDM from Merck Co. Ltd.. PGEi was dissolved in KRBG-BSA just before use. IDM was dissolved in 0.1M phosphate buffer pH9 in high concentration and then diluted with KRBG-BSA to an appropriate concentration.
Lysine-8-vasopressin (LVP) was kindly supplied by Sandoz Co. Ltd., and crude rat hypothalamic extracts (HE) by NIAMDD.
Duncan's new multiple range test was used for the comparison of the mean release of ACTH, prolactin, LH or GH in each beaker (Steel and Torrie, 1966) .
Results
Effects of PGE1 and IDM on the release of ACTH. The simultaneous addition of HE and PGE1 to the medium abolished the prolactin release induced by PGE1. Thus, it is conceivable that HE might contain an inhibitory substance which competes with PGE1 at the pituitary gland. Ojeda et al.(1974) found that a small amount of PGE1 injected into the 3rd ventricle in rats blocked an inhibition of prolactin release induced by dopamine. Hedqvist (1971) found that PGs of the E series inhibited the release of noradrenalin in response to the nerve stimulation in various tissues. Therefore, considering about the hypothalamus containing catecholamines, it is possible that PGE1 might inhibit the release of catecholamines on the hypothalamus in vivo.
The results that the addition of HE could not significantly stimulate the release of GH may be explained by the fact that HE contain not only GH-releasing factor but also somatostatin or another GH releaseinhibiting factor, and these hormones may cancel out each action at the pituitary gland. Ratner et al.(1973) reported that an in vitro addition of PGE1 over a concentration range of 10-7 to 10-5M enhanced the release of GH and 7-oxa-13-prostynoic acid, an antagonist of prostaglandins, reduced the stimulation of GH release found following the addition of PGE1. Ito et al. (1971) found intravenous drip infusion of PGE1 in man to induce a marked increase in GH secretion.
Recently, Sundberg et al.(1975) also reported that prostaglandins E1, E2, Fla or Fla significantly increased the release of rat GH in vitro. Our results on the GH release obtained in rats is consistent with their results.
Several investigators reported that PGs acted in inducing the release of LH-RH (Eskay et al., 1975; , and then caused the release of LH and FSH Sato et al., 1974) . found that PGE1 and PGE2 might be involved in the neural control of the pituitary gonadotropin release, and PGE1 had no direct effect on the release of gonadotropins at the pituitary level, but PGE2 had.
It is generally accepted that inhibitors of PGs synthesis (IDM and aspirin) interfere with the ovulation, and at least a part of the effect is caused at ovarian level (Carlson et al., 1974) . Recently, Ojeda et al.(1975) reported that inhibitors of PGs synthesis administered at high doses inhibited the LH release in the rat and this effect might be due to a direct effect of drugs on the central nervous system. On the other hand, Sundberg et al.(1975) found that IDM did not affect the basal LH release, but that it potentiated gonadotropin release in vitro stimulated by both HE and LH-RH.
Although it has not been clarified 
